This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Three Oversold BioTechs for Tired Gamblers:

Stocks in this article: IBB PCYC BIIB GILD

#2. Biogen (BIIB)

Cashtaggers buzzed Monday about this biotech winning FDA approval for a hemophilia B treatment. The company announced Friday that the FDA gave the go-ahead for its DNA-derived treatment to control bleeding episodes in patients who have trouble clotting.

The company, which has a $72.18 billion market cap, has many approved drugs, including treatments for multiple sclerosis, leukemia and non-Hodgkin's lymphoma. Last year, the company earned $2.1 billion, excluding some items, on $6.9 billion in sales.

Analysts have 20 Buy ratings and 8 holds on the stock, according to the Analyst Ratings Network. Consensus calls for a $317 price target. It currently trades at $305.12. Sentiment on the stock is 75% bullish, according to StockTwits' analytics.

One of the few good stocks to trade for today: $BIIB -- Selwyn Duijvestijn (@Marktgevoel) Mar. 31 at 09:51 AM

#3. Gilead Sciences (GILD)

This biotech giant with a $108 billion market cap is down nearly 16% in the past month. And that, say cashtaggers, is a buying opportunity. The stock rose 2% this morning.

$GILD $CELG $BIIB $REGN $IBB all showing strength in the pre-market, on high vol too -- Brandon (@brduke) Mar. 31 at 09:13 AM

Gilead is most often in the news regarding its Hepatitis C drug Sovaldi, which was approved in December last year. The drug costs $1,000 a day, which has raised the ire of some in Congress, but it can cure patients of the disease. Untreated, Hepatitis C can result in liver failure.

Sovaldi isn't Gilead's only blockbuster drug. It also makes treatments for HIV/AIDS, cystic fibrosis, the flu, macular degeneration, hypertension and cardiovascular disease. That's one reason why the company brought in $3.45 billion, excluding some items, on $11.2 billion in revenues last year.

Analysts have 24 buy ratings on the stock and 2 holds, according to the Analyst Ratings Network. Consensus price target is $88.92. The stock currently trades at $70.19. Sentiment on the name is 83% bullish, according to StockTwits' analytics.

$GILD @searchlight Calls working this morning. Good job. Conviction pays. -- Swingman24 (@Swingman24) Mar. 31 at 10:11 AM

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs